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Chemokines are the principal regulators of leukocyte migra-
tion and are essential for initiation and maintenance of inflam-
mation. Atypical chemokine receptor 2 (ACKR2) binds and
scavenges proinflammatory CC-chemokines, regulates cutane-
ous T-cell positioning, and limits the spread of inflammation in
vivo. Altered ACKR2 function has been implicated in several
inflammatory disorders, including psoriasis, a common and
debilitating T-cell–driven disorder characterized by thick ery-
thematous skin plaques. ACKR2 expression is abnormal in pso-
riatic skin, with decreased expression correlating with recruit-
ment of T-cells into the epidermis and increased inflammation.
However, the molecular mechanisms that govern ACKR2
expression are not known. Here, we identified specific psoria-
sis-associated microRNAs (miRs) that bind ACKR2, inhibit its
expression, and are active in primary cultures of human cutane-
ous cells. Using both in silico and in vitro approaches, we show
that miR-146b and miR-10b directly bind the ACKR2 3-UTR
and reduce expression of ACKR2 transcripts and protein in
keratinocytes and lymphatic endothelial cells, respectively.
Moreover, we demonstrate that ACKR2 expression is further
down-regulated upon cell trauma, an important trigger for the
development of new plaques in many psoriasis patients (the
Koebner phenomenon).We found that tensile cell stress leads to
rapid ACKR2 down-regulation and concurrent miR-146b up-
regulation. Together, we provide, for the first time, evidence for
epigenetic regulation of an atypical chemokine receptor. We
propose a mechanism by which cell trauma and miRs coordi-
nately exacerbate inflammation via down-regulation of ACKR2
expression and provide a putative mechanistic explanation for
the Koebner phenomenon in psoriasis.
Chemokines are members of a large family of chemotactic
cytokines that are the primary in vivo regulators of leukocyte
migration. Chemokines are central to the pathogenesis of
inflammatory diseases (1, 2) and interact with leukocytes
through members of the seven-transmembrane–spanning
family of G-protein–coupled receptors (3) to orchestrate the
recruitment of inflammatory cells into, and within, tissues.
Chemokines and their receptors are broadly categorized as
being either inflammatory or homeostatic according to the in
vivo contexts in which they function. Importantly, in addition
to the classical signaling chemokine receptors, there exists
a subfamily of chemokine-binding seven-transmembrane–
spanning molecules that are referred to as atypical chemokine
receptors (ACKRs).3 The ACKRs are promiscuous in their
ligand binding, tend to be expressed on stromal cells, and
are unable to mediate typical chemokine-induced signaling
responses following ligand binding (4–6).We have a particular
interest in one of these, ACKR2 (previously known as D6),
which is a high-affinity receptor formultiple inflammatory CC-
chemokines (5, 7, 8). ACKR2 does notmount classical signaling
responses following ligand binding (9) but internalizes ligands
and targets them for intracellular degradation (10, 11). Thus,
ACKR2 functions as a scavenger of proinflammatory chemo-
kines, and its dysfunction has been implicated in numerous
inflammatory diseases (6). In addition, ACKR2 is involved in
regulating a range of inflammation-dependent developmental
processes (12, 13).
ACKR2 expression is elevated in many human inflammatory
conditions, including rheumatoid arthritis (14), systemic scle-
rosis (15), and psoriasis (16). Psoriasis is a common systemic
inflammatory disease with profound effects associated with
both excess morbidity and mortality (17, 18). Psoriasis is typi-
cally characterized by clearly demarcated thick erythematous
skin plaques with white adherent scales surrounded by exten-
sive areas of apparently normal looking (unaffected) skin. Pso-
riatic plaques tend to preferentially develop in areas undergoing
repeated trauma such as the skin on the elbows and knees (19).
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Additionally, the Koebner phenomenon is frequently reported
in patients with psoriasis whereby relatively simple skin trauma
of unaffected skin leads to the rapid development of psoriatic
plaques in the vicinity of the preceding trauma (20).
In healthy skin, ACKR2 is primarily expressed by dermal
lymphatic endothelial cells and keratinocytes. ACKR2 expres-
sion in these cells helps to compartmentalize tissue inflamma-
tory responses to insult and infection by controlling the posi-
tion of inflammatory leukocytes (21–23). We have recently
shown that the spread of psoriasiform inflammation to unaf-
fected cutaneous sites is restricted by selective up-regulation of
cutaneous ACKR2 in the unaffected epidermis. At these sites,
high ACKR2 expression in keratinocytes limits local chemo-
kine activity and suppresses entry of T-cells into the epidermis,
thereby protecting against the development of plaques in unin-
volved skin. In contrast, skin in which ACKR2 expression is
relatively reduced is associated with enhanced inflammatory
chemokine activity, increased numbers of infiltrating T-cells in
the epidermis, and the emergence of inflammatory plaques
(24). The factors that trigger nascent plaque development in
psoriasis are not well understood, although our previous data
suggest that one such factor includes simple skin trauma, which
induces down-regulation of epidermal ACKR2 (16).
Despite the importance of epidermal ACKR2 in regulating
psoriasiform inflammation and its transcriptional response
to cutaneous trauma, the molecular mechanisms by which
ACKR2 expression is regulated in keratinocytes are not under-
stood. Here, by utilizing a combination of in silico and in vitro
approaches, we identify two psoriasis-associated microRNAs
that are up-regulated by trauma in primary cultures of human
keratinocytes. We show that the identified microRNAs bind
the ACKR2 3-untranslated region (3-UTR), resulting in
decreased expression at the transcript and protein levels. As
such, this is the first demonstration of known disease-associ-
ated miRNAs regulating atypical chemokine receptor expres-
sion and thereby modulating positioning of inflammatory
leukocytes within the skin. Importantly, our study highlights
a novel molecular mechanism by which trauma leads to the
development of new plaques in psoriasis (the Koebner
phenomenon).
Results
Three psoriasis-associatedmicroRNAs are predicted to bind
the ACKR2 3-UTR
MicroRNAs have emerged as the most abundant class of
gene regulators and have been implicated in a range of inflam-
matory disease processes. They predominantly act as negative
regulators of gene expression at a post-transcriptional level
(25). MicroRNAs bind their mRNA target 3-UTR, which leads
to mRNA degradation. Typically, one microRNA binds multi-
plemRNAtargets, and the samemRNA3-UTRcanbe targeted
by numerous microRNAs; this promiscuity introduces a signif-
icant degree of complexity in microRNA/target interactions
and subsequent regulation of gene expression (26). Recent
studies have shown that many microRNAs are differentially
expressed in psoriasis with a large number being significantly
overexpressed in the psoriatic plaques (27). Given their abun-
dance as negative regulators of gene expression, microRNAs
are thus plausible regulators of ACKR2 expression. Accord-
ingly, we used the bioinformatics database TargetScan to iden-
tify possible microRNA targets on the ACKR2 3-UTR. As
ACKR2 is present throughout mammals, results were filtered
such that only microRNAs that are broadly conserved among
vertebrates would be identified to increase the likelihood of
identified microRNA species being biologically relevant. Using
this search strategy, 16 microRNAs were identified that were
both 1) predicted to bind the 3-UTR of human ACKR2 and 2)
broadly conserved among vertebrates (the top 10 hits are shown
inFig. 1a).To further focus inon thosemicroRNAsof relevance to
psoriasis pathogenesis, we compared the list of microRNAs that
are predicted to bind the 3-UTRofACKR2withmicroRNAspre-
viously shown to be differentially expressed in psoriatic plaques
where ACKR2 expression is reduced relative to the surrounding
tissue (16). In this way, we identified three microRNAs that were
present in both lists, miR-10, miR-146, and miR-203. Notably,
eachof thesemiRNAshad aparticularly high in silico likelihoodof
regulating ACKR2 (Fig. 1, a and b). Additionally, these three
microRNAshave each been shown to play roles in skin homeosta-
sis and inflammation (28–30). They are thus plausible epigenetic
regulators of ACKR2 expression and were selected for further
evaluation.
miR-146b andmiR-10b reduce the expression of ACKR2mRNA
in primary human keratinocytes (KCs) and lymphatic
endothelial cells (LECs), respectively
KCs and LECs are the main ACKR2-expressing cells in skin
(16, 31). To ensure thatmicroRNAs could be successfully trans-
fected into primary KCs, cells were transfected with miR-146b
(most strongly up-regulated miRNA in psoriatic plaques; Fig.
1A) for 24 h, and the expression of two IFN-induced genes
known to be down-regulated bymiR-146b (IRAK1 andTRAF6)
was determined by Q-PCR (Fig. 2a). The data show a clear
ability of miR-146b to down-regulate levels of both transcripts,
thus demonstrating that microRNA could be successfully deliv-
ered into the cytoplasm of KCs. Primary KCs from at least two
separatehealthydonorswereused for all subsequent experiments.
Transfection of KCs with miR-146b significantly suppressed
ACKR2 mRNA expression; however, miR-10b and miR-203 had
no significant effects on ACKR2 transcript levels (Fig. 2b).
miR-146a and -b are differentially expressed in psoriasis, sug-
gesting non-redundant roles in this context (27), although our
in silico analyses predicted that miR-146a and miR-146b both
bind the ACKR2 3-UTR (Fig. 1a). To determine whether any
differences exist between miR-146a and miR-146b in the regu-
lation of ACKR2 expression, the two were directly compared
(Fig. 2c). BothmiR-146a andmiR-146bmediated a similar reduc-
tion inACKR2mRNAexpression inKCs after 24 hwith no signif-
icant differences between the two variants. Thus, both miR-146a
and miR-146b down-regulate ACKR2 transcript levels in KCs.
Next the threemicroRNAs were transfected into primary healthy
human dermal LECs, which also express high levels of ACKR2.
OnlymiR-10b significantly reducedACKR2mRNA expression in
LECs (Fig. 2d). Thus, these data demonstrate that psoriasis-asso-
ciatedmicroRNAs are capable of regulatingACKR2 expression in
keratinocytes and lymphatic endothelial cells.
MicroRNA regulation of ACKR2 expression
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miR-146b/miR-10b bind directly to the ACKR2 3-UTR
To determine whether miR-146b and miR-10b reduce
ACKR2 transcripts through direct interaction with the ACKR2
3-UTR, the 3-UTR of ACKR2 was cloned into a Dual-Lucif-
erase reporter vector (pmiRGLO vector). The ACKR2 3-UTR
containing putative miRNA target sites was inserted immedi-
ately 3 of a phosphoglycerate kinase promoter-driven firefly
luciferase gene to evaluate ACKR2 3-UTR–dependent
microRNA interactions on transcription. This construct was
transfected into HEK293 cells, and stable clones were selected.
These clones were then confirmed as being amenable to
microRNA transfection by assessing IRAK1 expression, which
Figure 1. In silico analyses identified several psoriasis-associated putative ACKR2 3-UTR–interactingmicroRNAs. a, summary ofmicroRNAs predicted
to bind the ACKR2 3-UTR with associated microRNA-specific data from previous psoriasis publications. The 10 microRNAs most likely to target ACKR2 are
included in the diagram with relevant findings in two papers given in the right-hand column. miR-10, miR-146, and miR-203 are all differentially regulated in
psoriasis (27, 37). In the figure, Footnote 1 is Ref. 37, and Footnote 2 is Ref. 27. b, three microRNAs (miR-10, miR-146, and miR-203) are predicted to bind the
ACKR2 3-UTR and are differentially expressed in psoriasis. The diagram showsmicroRNAs that are predicted to bind the ACKR2 3-UTR in silico and that have
been shown to be differentially expressed in psoriasis by microarray studies.
MicroRNA regulation of ACKR2 expression
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was significantly reduced following miR146b transfection (Fig.
3a). Having demonstrated that HEK cells could be transfected
with functional microRNAs of interest, we next determined
whethermiR-10 andmiR-146b transfectionmodulated lucifer-
ase activity (Fig. 3b). Both miR-10 and miR-146b transfection
significantly down-regulated luciferase activity in HEK cells,
Figure 2. miR-146 and miR-10 transfection reduced AKCR2 transcripts in KCs and LECs, respectively. a, absolute quantification of IRAK/TRAF6 mRNA
(previously validated miR-146b targets) in primary healthy human keratinocytes that were stimulated with 100 ng/ml human recombinant IFN prior to
transfection. b, absolute quantification of ACKR2 transcripts following transfection of KCs with miR-146b (i), miR-10 (ii), and miR-203 (iii). c, absolute quantifi-
cation of ACKR2 transcripts following transfection of KCs with miR-146a andmiR-146b. d, absolute quantification of ACKR2 transcripts following transfection
of LECs with miR-10 (i), miR-146b (ii), and miR-203 (iii). In all cases, cells were transfected for 24 h and left for a further 24 h prior to lysis and RNA extraction.
microRNAs were added at 10 nM; control is scrambled microRNA. Shown are representative experiments conducted in cells from various cell donors. Signifi-
cance was assessed using Student’s t test (*, p 0.05; **, p 0.01) except for dwhere significance was assessed using one-way ANOVAwith Tukey’s post-test
(*, p 0.05; **, p 0.01). Error bars represent S.E. NS, not significant; TBP, TATA-binding protein.
MicroRNA regulation of ACKR2 expression
3006 J. Biol. Chem. (2018) 293(8) 3003–3012
 at G
lasgow
 U
niversity Library on M
arch 14, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
although dual transfection with both miRs did not result in an
additive decrease. Thus, both miR-10 and miR-146b can medi-
ate a decrease in transcript levels through direct interactions
with the ACKR2 3-UTR.
miR-146b transfection of KC andmiR-10b transfection of LEC
reduced ACKR2 protein expression
Next we determined the effect of miR-146b on ACKR2 pro-
tein expression and distribution in primary KCs and LECs. For
reasons that are not immediately obvious, we have been unable
to successfully apply our functional ACKR2 assay (31) to pri-
mary keratinocytes. We have therefore relied on immunofluo-
rescence analysis to measure ACKR2 protein levels. Fully con-
fluent human KC monolayers (Fig. 4a with isotype control
shown in Fig. 4b) were transfected with miR-146b for 48 h, and
ACKR2 protein expression was determined by immunocyto-
chemistry. Bright green punctate cytoplasmic staining, typical
of ACKR2 expression in other cell types (11, 32), was observed
in KCs transfected with scrambled miR control (Fig. 4c). This
staining was more marked in the perinuclear region and often
in an asymmetrical fashion in keeping with higher ACKR2 lev-
els in the endoplasmic reticulum. This immunofluorescence
staining pattern is as expected, and we have previously pub-
lished that themajority ofACKR2protein is foundwithin intra-
cellular vesicles that traffic to, and from, the cell surface (11, 32).
In contrast, when monolayers of KCs were transfected with
miR-146b, cells exhibited a loss of ACKR2 staining throughout
the cytoplasm, although the perinuclear staining was still evi-
dent (Fig. 4d).
To investigate the effect ofmiR-10b onACKR2 expression in
human LECs, LECs that had been grown as confluentmonolay-
ers were transfectedwithmiR-10b, andACKR2 protein expres-
sionwas determined by immunofluorescence after 48 h (Fig. 5a
with isotype control shown in Fig. 5b). In keeping with the
known difference in ACKR2 transcript level, the level of
ACKR2 protein staining was less intense in LECs compared
with KCs. The granular staining in LECs was again more
marked to one side of the perinuclear region (akin to what was
observed in KCs), becoming especially apparent at higher mag-
nification (Fig. 5c). Importantly, ACKR2 staining was more
pronounced and more granular in scrambled miR control–
transfected LECs comparedwithmiR-10b–transfected LECs in
which staining was not higher than background autofluores-
cence (Fig. 5, b and d). Taken together, immunofluorescence
Figure 3. miR-146b and miR-10b functionally interact with the ACKR2 3-UTR. a, miR-146b can be successfully transfected into HEK293 cells. Absolute
quantification of IRAK1 mRNA was assessed by Q-PCR in HEK293 cells following transfection with miR-146b as compared with scrambled control. b, ACKR2
3-UTRwas cloned into the downstreamUTR of a firefly luciferase reporter, and interactionwith transfectedmiRs was determined (bioluminescence inversely
proportional to microRNA 3-UTR binding) and normalized to Renilla luciferase. Results are representative from two different luciferase-expressing HEK293
clones following transfection with miR-10b and miR-146b (singly and in combination) and scrambled miR control. Significance was assessed using one-way
ANOVA (***, p 0.005). Error bars represent S.E. TBP, TATA-binding protein.
Figure4. TransfectionofKCswithmiR-146b reduced cytoplasmicACKR2
protein distribution. a, representative bright-field image of KCs grown as a
confluentmonolayer.b, representative immunofluorescenceof KCsgrownas
confluent monolayers and stained with isotype control antibody. c and d,
representative immunofluorescencemicroscopy images of confluent mono-
layers of KCs 48 h after transfection with scrambled miR control (c) or miR-
146b (d).
MicroRNA regulation of ACKR2 expression
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staining of cultured cell monolayers demonstrated that trans-
fection with miR-146b in KCs and miR-10b in LECs led to a
reduction in ACKR2 staining in both cell types by 48 h.
Tensile cell trauma of cytokine-treated KC leads to a rapid
reduction in ACKR2mRNA expression
Next we examined the possible relevance of our finding for
cutaneous inflammatory responses such as those typical of pso-
riasis. Psoriatic patients have elevated cutaneous ACKR2
expression in unaffected skin, which mouse models suggest
may offer protection from further lesion development (24).
Superficial trauma of unaffected skin in psoriatic patients can
trigger psoriatic plaque development (koebnerization) concur-
rent with ACKR2 expression down-regulation (16, 33, 34). This
phenomenon is a feature of many psoriatic patients where
lesions have a particular predilection for sites that undergo
repeated stretching in daily life (e.g. knees, elbows, and skin
folds) (20). Thus, we wanted to determine whether tensile
trauma down-regulated ACKR2 in cultured keratinocytes in a
cell-autonomous manner and whether this correlated with
increasedmiR-146 activity. To specifically determine the effect
of tensile cell trauma on ACKR2 expression, a reductionist in
vitromodel was developed. Themodel developed was based on
the FlexCellTM International FX5000 machine whereby pri-
mary human cells were grown on silicone membranes. The
membrane was subsequently subjected to repeated biaxial
cyclical tension in vitrowith a predetermined degree of tension,
stretchwaveform, and cycle number (thismodel is summarized
in Fig. S1). Neither KCs nor LECs adhered to uncoated silicone,
and therefore KCs were grown on collagen I–coated silicone,
whereas LECs were grown on fibronectin-coated silicone. This
was found to be associated with stable cell attachment over a
12-h stretch cycle for each cell type.
To examine the effect of tensile trauma on KC ACKR2
expression, confluent KC monolayers were subjected to
stretching for 12 h during which the membrane was stretched
by 15% every 0.8 s (0.8 Hz), which is not atypical for skin sites
such as elbows that are exposed to daily repeated stretching.
Cells were rested for a further 12 h before lysis to enable gene
expression and ACKR2 expression determined by Q-PCR. The
data obtained (Fig. 6a) showed that stretching of non-inflamed
KCs did not result in altered ACKR2 expression. However,
these primary human cells are derived fromhealthy donors and
are grown in the absence of typical psoriasis-associated factors.
Psoriasis patients have markedly elevated T-cell cytokines,
including IFN, that correlate with elevated ACKR2 in unaf-
fected skin (16, 24). Therefore, to bettermodel human psoriasis
where KCs exist in the context of systemically elevated T-cell
cytokines, KCs were treated with either tissue culture superna-
tant from activated human T-cells or recombinant IFN (both
of which up-regulate ACKR2 expression (16, 24)) and then
exposed to tensile stress for 12 h at 0.8 Hz. In contrast to non-
treated KCs (Fig. 6a), tensile trauma of KCs pretreated with
T-cell supernatants led to a significant decrease in ACKR2
expression (Fig. 6b). This was also the case for IFN-pretreated
KCs, suggesting that KCs with elevated ACKR2 levels such as
those found in psoriasis patients display tensile stress–induced
down-regulation of expression. Interestingly, treatment of the
T-cell supernatant with IFN-neutralizing antibodies did not
diminish this effect, suggesting that soluble T-cell products
other than IFN can mediate the observed effect (Fig. 6b). In
contrast toKCs, therewas no effect onACKR2 expression upon
flexing of LECs that were stimulated with T-cell supernatant
(Fig. 6c). Thus, the response of inflamedKC and LECs to tensile
stress appears to be different even when cells have been simi-
larly pretreated.
To determine whether there was a possible link between
these observations and alterations in miR-146b expression,
miR-146a/b expression levels were quantified by Q-PCR in
inflamedKCs. BothmiR-146a andmiR-146bwere up-regulated
in KCs that had been treated with tissue culture supernatant
from activated human T-cells compared with resting non-in-
flamed KCs (Fig. 6d, gray bars). Importantly, when these cells
were subjected to tensile trauma, this effect was dramatically
amplified; there was an over 100-fold induction of miR-146a
and a lesser (albeit significant) induction of miR-146b (Fig. 6d,
black bars). A similar observationwas found for KCs pretreated
with recombinant IFN and then subjected to stretching,
although in this casemiR-146bwasmore strongly induced than
miR-146a (Fig. 6e). Taken together, these data suggest that KCs
exposed to psoriasis-associated T-cell cytokines markedly up-
regulate miR-146a/b expression concurrently with ACKR2
down-regulation upon stretching and provide a putativemech-
anistic link that explains theKoebner phenomenon in psoriasis.
Figure 5. Transfection of LECs with miR-10 reduced ACKR2 protein
expression throughout the cytoplasm.a, representativebright-field image
of LECs grown as a confluent monolayer. b, representative immunofluores-
cence of LECs grown as confluent monolayers and stained with isotype con-
trol antibody. c and d, representative immunofluorescence microscopy
images of confluent monolayers of LECs 48 h after transfection with scram-
bledmiR control (c) or miR-10 (d).White arrows indicate asymmetric distribu-
tion of ACKR2.
MicroRNA regulation of ACKR2 expression
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Discussion
The atypical chemokine receptorACKR2 is expressed in bar-
rier tissues, including the skin, and functions as a high-capacity
scavenger of proinflammatory CC-chemokines. In vivo and
specifically in the context of psoriasiform inflammation, we
have shown that ACKR2 restricts T-cell entry into the epider-
mis and limits inflammation. Additionally, ACKR2 expression
is deficient in psoriatic plaques in humans, which may enable
uncontrolled inflammation and thereby plaque formation. The
mechanism by which ACKR2 down-regulation occurs has,
until now, not been described. Indeed, although some proin-
flammatory cytokines are known to increase expression of
ACKR2 (although notably not the psoriasis-associated cytokine
IL-17 (16, 24)), little is known about themolecularmechanisms
that control atypical chemokine receptor expression. Here, we
identify microRNAs that are both differentially expressed in
psoriasis and predicted to target the ACKR2 3-UTR. Experi-
mental evidence is provided that miR-146 and miR-10 bind
Figure 6. Effect of tensile stress on ACKR2 expression by primary human KCs. a–c, absolute quantification of ACKR2mRNA normalized to TATA-binding
protein (TBP) in keratinocytes. a, healthy humanprimary KCs that remained static orwere subjected to tensile stress (flexed) at 0.8 Hz for 12 h and then allowed
to rest for 12 h prior to cell lysis and RNA extraction. b, healthy human primary KCs that remained static or were subjected to tensile stress (flexed) at 0.8 Hz for
12 h and then allowed to rest for 12 h prior to cell lysis and RNA extraction. KCs were pretreated with either 1) tissue culture supernatant from activated
human T-cells (1:8 dilution in fresh medium), 2) 100 ng/ml recombinant human IFN, or 3) tissue culture supernatant from activated human T-cells plus
neutralizing anti-IFN antibodies overnight prior to flexing at 0.8 Hz for 12 h. Black bars, non-flexed static controls; gray bars, flexed cells. Significance
was assessed using one-way ANOVA. c, treatment of healthy primary LECs overnight with tissue culture supernatant from activated human T-cells
(diluted 1:8 with fresh medium) prior to flexing. d and e, effect of tensile stress on miR-146 expression in inflamed keratinocytes. -Fold change in
miR-146a and miR-146b expression was assessed by Q-PCR and normalized to scrambled miR–treated static KCs. KCs were treated for 16 h with either
tissue culture supernatant from activated human T-cells (1:8 dilution in fresh medium) (d) or recombinant IFN- at 100 ng/ml (e) prior to flexing at 0.8
Hz for 12 h. Error bars represent S.E. NS, not significant.
MicroRNA regulation of ACKR2 expression
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directly to theACKR2 3-UTR and lead to a down-regulation of
ACKR2 at transcript and protein levels in KCs and LECs,
respectively.
It is notable that we saw, at best, a 50% reduction in luciferase
activity, or ACKR2 transcript levels, in cells transfected with
miR-146 species. It is widely accepted that this level of tran-
script knockdown represents a typical response to miR-medi-
ated suppression and that more extensive depletion of target
mRNA levels is not commonly seen (35, 36).
We have previously shown that mild trauma (tape-stripping,
which induces a mild degree of epidermal damage and tensile
stress) to uninvolved psoriatic skin leads to rapid transcrip-
tional down-regulation of ACKR2, which, we propose, allows
chemokine-dependent inflammation to become established
and contributes to the Koebner phenomenon and development
of plaques (16). The Koebner phenomenon is reported in pso-
riasis as well as a range of other skin diseases whereby skin
trauma (for example scratching and tape-stripping) triggers the
appearance of the underlying disease at those sites (20). How-
ever, tape-stripping induces several types of damage to skin,
including disruption of skin barrier function as well as tensile
stress during the rapid removal of the tape adherent to skin.
Additionally, it is notable that psoriatic plaques have a predi-
lection for areas undergoing repeated tension, e.g. elbows,
knees, and skin folds. To specifically mimic tensile trauma to
keratinocytes in vitro, we used a cell-flexing device to induce
tensile stretch across the length of the keratinocytes. Flexing of
resting keratinocytes, which express very lowACKR2 levels, did
not alter transcript levels. In comparison, flexing of keratino-
cytes pretreated with conditioned medium from activated
human T-cells significantly reduced elevated ACKR2 expres-
sion. This was also seen with stretching of IFN-treated kerati-
nocytes. Together, our results demonstrate that, although kera-
tinocyte trauma does not alter ACKR2 expression under
“resting” conditions, it does nonetheless significantly reduce
T-cell–inducedACKR2 expression levels, thusmimickingwhat
is seen in uninvolved human psoriatic skin upon trauma (16).
Despite being well described, a mechanism for the Koebner
phenomenon (koebnerization) has not been elucidated. Our
findings presented here provide a novel molecular mechanism
by which koebnerization might be induced in unaffected psori-
atic skin, potentially through the up-regulation of miR-146
and its interaction with ACKR2 transcripts. To this end, we
defined the impact of flexing on miR-146 expression in T-cell
supernatant–treated keratinocytes. These analyses revealed a
marked induction of miR-146a (and to a lesser extent miR-
146b) in flexed, compared with static, T-cell–treated keratino-
cytes. These data therefore indicate that increased expression
of miR-146 followingmild trauma to keratinocytes, and in pso-
riatic plaques, is able to counteract the inductive effects of acti-
vated T-cell products on ACKR2 expression. Thus, these find-
ings also provide a plausible mechanistic explanation for the
Koebner phenomenon in inflammatory skin diseases such as
psoriasis and may have wider implications for non-cutaneous
inflammatory diseases in which tensile strength is a contribut-
ing factor, e.g. rheumatoid arthritis.
Experimental procedures
MicroRNA in silico selection
MicroRNAs that were predicted to bind to the 3-UTR
of ACKR2 were identified using TargetScan version 6.2 (www.
targetscan.org).4 MicroRNAs with the highest likelihood of
binding the ACKR2 3-UTR (as indicated by the total context,
CT, score) and that were concurrently identified as being up-
regulated in psoriatic plaques in humans were selected for fur-
ther study (27, 37).
Cell culture
Primary healthy human KCs and LECs were purchased (Pro-
moCell, Heidelberg, Germany) and cultured according to the
manufacturer’s instructions in KCGM2 and ECMV2 medium,
respectively (PromoCell). All in vitro experimental work was
conducted at passage 3–4 at 70% confluence (averaged across
the vessel). All cells were maintained at 37 °C in a humidified
tissue culture incubator with 5% CO2. Cells were grown in the
presence of 1% penicillin/streptomycin (Sigma) and 0.1% gen-
tamicin solution (50 mg/ml; Sigma). Experiments in primary
human cells were generally repeated using cells from at least
two separate cell donors.HEK293 cell lineswere kindly donated
by Dr. K. Hewit and grown in DMEM (Sigma) to which was
added 50 ml of fetal calf serum and 5 ml of L-glutamine/500 ml
(Sigma). Data representative of two or more independent
experiments with a minimum of three replicates for each
experiment.
MicroRNA transfection of cells
Cells were transfected with Lipofectamine RNAiMAX
according to the manufacturer’s instructions (Thermo Fisher).
Cell culturemediumwas changed to antibiotic-free equivalents
24 h prior to transfection and maintained antibiotic-free
throughout the transfection process. Cells were transfected at
70% confluence. MicroRNAs, scrambled microRNA control,
andmiR inhibitors (mirVana, Thermo Fisher) were transfected
according to the manufacturer’s in 50 l of Opti-MEM
(reduced serum medium; Thermo Fisher). Transfection was
allowed to occur at 37° for 24 h before the cells were lysed (or
the medium was changed for prolonged incubation). At this
concentration, the microRNAs had no detectable effect on cell
viability.
RNA extractions and quantitative PCR
RNAwas extracted and purified onRNeasymicrocolumns or
miRNeasy columns (Qiagen) with on-column DNase (Qiagen)
digestion according to the manufacturer’s instructions. Whole
tissue samples were homogenized in Qiazol with stainless steel
beads using a TissueLyser LT (Qiagen). 1 g of total RNA was
reverse transcribed using nanoScript RT or RT2 kits according
to the manufacturer’s instructions (PrimerDesign, UK). For
samples intended for microRNA Q-PCR, 440 ng of total RNA
was reverse transcribed using anmiScript II RT kit according to
themanufacturer’s instructions (Qiagen). Sampleswere diluted
4 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party-hosted site.
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1:5 in nuclease-free water prior to being used as a template for
Q-PCR. Gene transcripts were quantified by quantitative PCR
analysis using Perfecta SYBR Green Master Mix according to
the manufacturer’s instructions (Quanta, UK). Samples were
analyzed in quadruplicate on a 384-well Applied Biosystems
7900HT platform (Life Technologies). ACKR2 transcript levels
were normalized to human TATA-binding protein. The
sequences for the Q-PCR primers were as reported previously
(16, 31, 38) except for TRAF6 and IRAK1. For samples intended
for microRNA quantification, Q-PCR was performed using the
miScript SYBR Green PCR kit with primers for miR-146a and
146b normalized to RNU6B expression (all from Qiagen and
according to the manufacturer’s instructions) and analyzed on
a 384-well Applied Biosystems 7900HT. Results for microRNA
were analyzed according to the method rather than semia-
bsolute methods as used for mRNA.
LuciferasemicroRNA assay
The 3-UTR of ACKR2 was cloned into the Dual-Luciferase
system containing the pmiRGLO vector (Promega). The
3-UTR region was sequenced to ensure putative microRNA-
binding sites were intact (Eurofins, UK).
The plasmid was transfected into HEK293 cells, and stable
transfectants were generated through selection with 0.8 mg/ml
G418 (Promega). Non-ACKR2–containing pmiR vector was
transfected as a control. HEK293 cells were donated by Dr. K
Hewit and grown in DMEM (Sigma) with added penicillin/
streptomycin as described above. Several clones were identified
for further testing, and two of these clones were transfected
with the relevant microRNAs/controls, cells were lysed, and
firefly luciferase activity was normalized to Renilla luciferase
(Promega) according to themanufacturer’s instructions. pmiR-
containing HEK293 cells (i.e. with no ACKR2 3-UTR) and
native HEK293 cells were used as controls in the assay, which
was repeated using two separate HEK293 clones.
Fluorescent immunocytochemistry
Cells were cultured in 4-well chamber slides (Thermo Scien-
tific Nunc or BD Falcon). Slides were washed in phosphate-
buffered saline (PBS) without calcium (Sigma) and fixed with
100%methanol. Slides were washed and blocked with 20% nor-
mal horse serum in PBS with 0.05% Tween (Sigma) followed by
an avidin/biotin block. Slides were stained for ACKR2 using
Sigma Prestige anti-human ACKR2 IgG antibody (Sigma)
raised in rabbit in 2.5% normal human serum and 2.5% horse
serum (Vector Laboratories, UK) in PBS-Tween overnight at
4 °C and then stained with a secondary antibody (biotinylated
anti-rabbit IgG raised in goat with 5% human serum). Slides
were washed, incubated with Avidin-D fluorochrome conju-
gated with FITC (Vector Laboratories), and mounted with
Vectamount containing DAPI (Vector Laboratories) prior to
visualization through confocal microscopy (LSM510, Zeiss).
Tensile stress of keratinocytes
For FlexCell experiments, primary human keratinocytes
were grown in BioFlex 6-well plates precoated with collagen I
(FlexCell International) for KCs or plain BioFlex 6-well plates
coatedwith fibronectin overnight prior to use (Sigma) for LECs.
Cells were subjected to tensile stress at 15% effective stretch, 0.8
Hz, and half-sine waveform using the FlexCell FX5000 cell ten-
sion system (FlexCell International). Cells were stretched for
12 h and rested for a further 12 h prior to lysis. All cells were
grown and subjected to tension in a humidified incubator at
37 °C with 5% CO2.
T-cell isolation and stimulation
Human T-cells were grown from CD14-depleted human
buffy coats from healthy donors and stimulated with conca-
navalin A (5 ng/ml; Sigma) and grown in RPMI 1640 medium
(Life Technologies) with 5% human AB serum and gentamicin
(Sigma) in the presence of IL-2 (20 units/ml; Peprotech, UK)
from day 4. Cells were purified on Ficoll-Paque after 8 days (GE
Healthcare) and grown in the presence of IL-2 alone for 4 days
before being activated using CD2/CD3/CD28 beads according
to the manufacturer’s instructions at a 1:2 bead:cell ratio
(Miltenyi Biotec,UK) for 24 h prior to the activated supernatant
being removed for downstream applications. Where T-cell
supernatant was to be used for KC/LEC stimulation, T-cells
were grown in serum-free keratinocyte medium KCGM2 or
ECMV2 with added supplements during the 24-h activation
period (PromoCell). T-cells used formigration assayswere sim-
ilarly activated albeit at a 1:4 bead:cell ratio for 48 h prior to use.
Statistical analyses
Student’s t test, one-way ANOVA, two-way ANOVA,
and correlation tests were performed in Prism version 7.0
(GraphPad Software Inc.) with multiple comparison tests as
appropriate.p 0.05was deemed significant. All data aren 3,
representative of at least two independent experiments, and
given as mean S.E. unless otherwise stated.
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